<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503126</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-BIV-07-01</org_study_id>
    <nct_id>NCT00503126</nct_id>
  </id_info>
  <brief_title>Bivalirudin as a Procedural Anticoagulant in Pediatrics</brief_title>
  <official_title>Bivalirudin (Angiomax®) As A Procedural Anticoagulant In The Pediatric Population Undergoing Intravascular Procedures For Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and safety of weight based bivalirudin in children&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK/PD and safety</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Cardiology</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalirudin</intervention_name>
    <description>anticoagulation</description>
    <other_name>Angiomax/Angiox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and non-pregnant females, with an age range of birth to 16 years of age.&#xD;
&#xD;
          -  Expected to undergo a percutaneous intravascular procedure for the management of&#xD;
             congenital heart disease.&#xD;
&#xD;
          -  Written informed consent from a legal guardian/parent.&#xD;
&#xD;
          -  Life expectancy of at least 15 days at study entry.&#xD;
&#xD;
          -  Assent of the patient if older than 8 years, whenever possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intracerebral bleed (neonates confirmed by an ultrasound head scan prior to&#xD;
             procedure), or cerebral arteriovenous malformation or any prior bleed with&#xD;
             neurological deficit.&#xD;
&#xD;
          -  Gastrointestinal or genitourinary bleeding within the last 2 weeks excluding normal&#xD;
             menstrual cycles.&#xD;
&#xD;
          -  Cerebrovascular accident within 6 months, or any cerebrovascular accident with a&#xD;
             residual neurological deficit.&#xD;
&#xD;
          -  Known congenital or acquired bleeding or clotting disorder.&#xD;
&#xD;
          -  Patients undergoing renal dialysis.*&#xD;
&#xD;
          -  Weight &lt; 2.5 kg.&#xD;
&#xD;
          -  Confirmed pregnancy at time of enrollment or breast feeding (females of child-bearing&#xD;
             potential).&#xD;
&#xD;
          -  Known allergy to bivalirudin or hirudin-derived drugs, or known sensitivity to any&#xD;
             component of bivalirudin (Angiomax®).&#xD;
&#xD;
          -  Any condition that in the investigator's opinion would constitute a contraindication&#xD;
             to participation in the study, or cause inability to comply with the study&#xD;
             requirements.&#xD;
&#xD;
          -  Participation in another investigational therapeutic drug or therapeutic device trial&#xD;
             within 30 days of starting study.&#xD;
&#xD;
          -  Patients who have been receiving warfarin (Coumadin®) therapy and whose INR is &gt; 1.5.&#xD;
&#xD;
          -  Patients who cannot be discontinued from UFH at least 30 minutes prior to study drug&#xD;
             bolus.&#xD;
&#xD;
          -  Patients who have received a dose of LMWH within 8 hours prior to study drug bolus.&#xD;
&#xD;
          -  Patients previously enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>bivalirudin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 15, 2020</submitted>
    <returned>November 5, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

